Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...

New potential therapeutic targets have been identified for diabetic kidney disease (DKD) - the leading cause of kidney ...

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Brandy Verdin, 49, lives with her husband in Gray, Louisiana. She was diagnosed with Stage IV renal cell carcinoma in May 2023.

Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...

In every issue, you’ll find cutting-edge health information and the hottest topics of interest to people with cancer and ...

Subsequent leukemia was associated with high cumulative doses of epipodophyllotoxins, older age at initial cancer diagnosis, and receipt of hematopoietic stem cell transplant.

For many smaller innovators, bringing a promising molecule from the lab through clinical trials and onto the market is a ...

AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), pote ...

Craig Cynkin, a kidney cancer survivor and ultramarathon enthusiast, is set to compete in the 32nd 100km World Running Championship in Bengaluru. This inspiring athlete, who has battled cancer twice, ...

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics ...